Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02426229 · ClinicalTrials.gov registry record · Phase 1
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02426229 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 15 participants.
The verdict
NCT02426229, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study evaluates if dabigatran etexilate is safe for use in patients with Scleroderma and Interstitial Lung Disease. All patients will receive 75mg of dabigatran etexilate twice a day for 6 months.
Interventions
- DRUG dabigatran etexilate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-06-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02426229
The ClinicalTrials.gov registry entry for NCT02426229 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dabigatran etexilate is the first listed.
NCT02426229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02426229 about?
NCT02426229 is a clinical study titled "Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma". This study evaluates if dabigatran etexilate is safe for use in patients with Scleroderma and Interstitial Lung Disease. All patients will receive 75mg of dabigatran etexilate twice a day for 6 months.
What is the current status of trial NCT02426229?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2016-02. Estimated completion is 2018-06-21.
What interventions are being tested in trial NCT02426229?
The interventions under investigation include: dabigatran etexilate (DRUG).
Who is sponsoring clinical trial NCT02426229?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.